1. Home
  2. CELU vs SPAI Comparison

CELU vs SPAI Comparison

Compare CELU & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELU
  • SPAI
  • Stock Information
  • Founded
  • CELU 2016
  • SPAI 2021
  • Country
  • CELU United States
  • SPAI United States
  • Employees
  • CELU N/A
  • SPAI N/A
  • Industry
  • CELU Biotechnology: Pharmaceutical Preparations
  • SPAI Industrial Specialties
  • Sector
  • CELU Health Care
  • SPAI Health Care
  • Exchange
  • CELU Nasdaq
  • SPAI Nasdaq
  • Market Cap
  • CELU 42.2M
  • SPAI 38.5M
  • IPO Year
  • CELU N/A
  • SPAI 2024
  • Fundamental
  • Price
  • CELU $3.86
  • SPAI $6.70
  • Analyst Decision
  • CELU Buy
  • SPAI Strong Buy
  • Analyst Count
  • CELU 1
  • SPAI 1
  • Target Price
  • CELU $6.00
  • SPAI $8.00
  • AVG Volume (30 Days)
  • CELU 66.2K
  • SPAI 526.4K
  • Earning Date
  • CELU 10-15-2025
  • SPAI 08-14-2025
  • Dividend Yield
  • CELU N/A
  • SPAI N/A
  • EPS Growth
  • CELU N/A
  • SPAI N/A
  • EPS
  • CELU N/A
  • SPAI N/A
  • Revenue
  • CELU $44,590,000.00
  • SPAI $1,496,091.00
  • Revenue This Year
  • CELU $23.29
  • SPAI N/A
  • Revenue Next Year
  • CELU N/A
  • SPAI N/A
  • P/E Ratio
  • CELU N/A
  • SPAI N/A
  • Revenue Growth
  • CELU 138.11
  • SPAI 7.49
  • 52 Week Low
  • CELU $1.00
  • SPAI $1.47
  • 52 Week High
  • CELU $5.22
  • SPAI $7.39
  • Technical
  • Relative Strength Index (RSI)
  • CELU 60.90
  • SPAI 68.15
  • Support Level
  • CELU $3.52
  • SPAI $5.80
  • Resistance Level
  • CELU $4.01
  • SPAI $7.39
  • Average True Range (ATR)
  • CELU 0.34
  • SPAI 0.68
  • MACD
  • CELU -0.01
  • SPAI 0.26
  • Stochastic Oscillator
  • CELU 64.84
  • SPAI 78.36

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About SPAI Safe Pro Group Inc. Common Stock

Safe Pro Group Inc operates to acquire security and protection products. Its emphasis is on the development of a cloud-based ecosystem for analyzing drone imagery and data utilizing proprietary artificial intelligence (AI), machine learning, deep learning, and applied computer vision software for hyper-scalable processing, analysis, and reporting. The company operated in three reportable business segments which consisted of: the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. Key revenue is generated from Airborne Response.

Share on Social Networks: